Immunohistochemistry and the diagnosis of malignant mesothelioma

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Histopathology

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2559.2001.01092.xPMID 11422486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.

  2000cited by this paper
• Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.

  2000cited by this paper
• HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma

  2000cited by this paper
• Laser-induced acoustic emissions in experimental dental composites.

  2000cited by this paper
• Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms

  2000cited by this paper
• The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis

  1999cited by this paper
• Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

  1999cited by this paper
• Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update.

  1999cited by this paper
• Histological Classification of Lung and Pleural Tumours

  1999cited by this paper
• Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.

  1999cited by this paper
• MOC‐31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells

  1999cited by this paper
• E‐cadherin, N‐cadherin, and calretinin in pleural effusions: The good, the bad, the worthless

  1999cited by this paper
• Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.

  1998cited by this paper
• Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases

  1998cited by this paper
• TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.

  1998cited by this paper
• Malignancy metastatic to the pleura.

  1998cited by this paper
• E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma

  1998cited by this paper
• Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.

  1998cited by this paper
• Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma

  1997cited by this paper
• Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.

  1997cited by this paper
• Immunophenotyping of malignant mesothelioma.

  1997cited by this paper
• The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.

  1997cited by this paper
• Pathology of malignant mesothelioma

  1997cited by this paper
• CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma

  1997cited by this paper
• The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.

  1997cited by this paper
• Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.

  1997cited by this paper
• Calretinin: a novel immunocytochemical marker for mesothelioma.

  1996cited by this paper
• Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases

  1996cited by this paper
• Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas.

  1996cited by this paper
• Spencer's Pathology of the Lung

  1996cited by this paper
• The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.

  1996cited by this paper
• Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma

  1996cited by this paper
• Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.

  1996cited by this paper
• Primary pulmonary sarcomas with features of monophasic synovial sarcoma: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases.

  1995cited by this paper
• The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.

  1995cited by this paper
• OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.

  1995cited by this paper
• Tumors of the serosal membranes

  1995cited by this paper
• Continuing increase in mesothelioma mortality in Britain.

  1995cited by this paper
• Malignant mesothelioma of the pleura: interobserver variability.

  1995cited by this paper
• Hemangiopericytoma: histopathological pattern or clinicopathologic entity?

  1995cited by this paper
• Malignancies in the lung and pleura mimicking benign processes.

  1995cited by this paper
• Immunohistochemical diagnosis of mesothelioma

  1994cited by this paper
• Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases

  1994cited by this paper
• Prognostic factors of malignant mesothelioma of the pleura

  1993cited by this paper
• Sarcomatoid carcinoma of the lung. Immunohistochemieal and ultrastructural studies of 14 cases

  1992cited by this paper
• Lung carcinoma with spindle cell components: sixteen cases examined by immunohistochemistry.

  1992cited by this paper
• Desmoplastic malignant mesothelioma: a review of 17 cases.

  1992cited by this paper
• Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma.

  1992cited by this paper
• Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma

  1991cited by this paper
• Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.

  1991cited by this paper
• Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.

  1990cited by this paper
• Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies.

  1990cited by this paper
• Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.

  1989cited by this paper
• Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas

  1989cited by this paper
• Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.

  1988cited by this paper
• Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: an immunoperoxidase study of 30 cases.

  1988cited by this paper
• Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.

  1988cited by this paper
• Monoclonal antibodies to human malignant mesothelioma

  1987cited by this paper
• Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

  1986cited by this paper
• Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases

  1986cited by this paper
• Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases

  1986cited by this paper
• Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure.

  1983cited by this paper
• Desmoplastic diffuse mesothelioma

  1982cited by this paper
• Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers

  1979cited by this paper
• Benign pleural lesions and malignant mesothelioma

  1977cited by this paper
• Soft tissue tumours.

  1973cited by this paper
• Pleural disease.

  1961cited by this paper

• Mezotelyoma ve akciğer adenokarsinomunun ayırıcı tanısında immünohistokimyasal belirteçlerden calretinin, D2-40, p63 ve tiroid transkripsiyon faktör-1'in rolü

  2023cites this paper
• A Case of Malignant Mesothelioma of the Peritoneum with Sporadic Weak Positivity to TTF-1

  2019cites this paper
• Tumors of the lung and mediastinum

  2014cites this paper
• Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma

  2011cites this paper
• Occupational toxicology of asbestos-related malignancies

  2010cites this paper
• Malignant Desmoplastic Type Mesothelioma Mimicking a Fibrous Pseudotumor of the Tunica Vaginalis: A Case Report and Literature Review

  2009cites this paper
• Molecular profiling of malignant pleural mesothelioma and pulmonary fibrosis

  2009cites this paper
• A biphasic malignant mesothelioma of the peritoneum and pleura in a horse.

  2009cites this paper
• BTS statement on malignant mesothelioma in the UK, 2007

  2007cites this paper
• Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma

  2007cites this paper
• Pathology quiz case 1. Metastatic mesothelioma involving the tongue.

  2006cites this paper
• Management of malignant pleural mesothelioma.

  2006cites this paper
• Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data

  2006cites this paper
• Use of Immunohistochemical Marker Calretinin in the Diagnosis of a Diffuse Malignant Metastatic Mesothelioma in an Equine

  2004cites this paper
• Pathology of malignant mesothelioma.

  2004cites this paper
• Lymphohistiocytoid Mesothelioma: A Clinical, Immunohistochemical and Ultrastructural Study of Four Cases and Literature Review

  2004cites this paper
• Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis

  2004cites this paper
• Pathology of mesothelioma.

  2004cites this paper
• Pathology of malignant mesothelioma.

  2004cites this paper
• Asbestos-induced peritoneal mesothelioma in a construction worker.

  2003cites this paper
• Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies

  2002cites this paper
• Algunas consideraciones sobre la inmunohistoquímica en el diagnóstico diferencial entre Mesotelioma y Adenocarcinoma

  2002cites this paper
• Antioxidant enzymes and related mechanisms in malignant pleural mesothelioma

  2001cites this paper
• Modern Immunohistochemistry by Peiguo Chu

  2000cites this paper